Not finding it? Sign in to also search OpenAlex live.
-
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
407citations -
Plain Language Summary of PEGASUS, a Study Comparing Pegcetacoplan with Eculizumab for 16 Weeks in People with Paroxysmal Nocturnal Hemoglobinuria2023 Future Rare Diseases article Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
0citations -
Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)2024 Future Rare Diseases article Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +10 more
0citations -
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study2024 Advances in Therapy article Immunology and Microbiology Complement system in diseases Open access
Christopher Jordan Patriquin, Andrija D. Bogdanovic, Morag Griffin, Richard J. Kelly, Jaroslaw Pawel Maciejewski, Brian Patrick Mulherin, +9 more
20citations -
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +3 more
3citations -
Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Koo Wilson, Jesse Fishman, Piotr Wojciechowski, Marlena Wdowiak, Regina Horneff, +3 more
6citations -
Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function2024 International Journal of Molecular Sciences article Immunology and Microbiology Complement system in diseases Open access
Jeff Szer, Jens Panse, Austin Gladston Kulasekararaj, Monika Oliver, Bruno Fattizzo, J Nishimura, +3 more
4citations -
P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +4 more
0citations -
P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
Jeff Szer, Jens Panse, Austin Gladston Kulasekararaj, Monika Oliver, Bruno Fattizzo, Jun‐ichi Nishimura, +3 more
1citations -
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial2022 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +12 more
74citations -
RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATING SUPERIORITY OF THE C3 INHIBITOR PEGCETACOPLAN COMPARED TO ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA2020 Hematology Transfusion and Cell Therapy article Immunology and Microbiology Complement system in diseases Open access
Peter Hillmen, Jeff Szer, Britta Höchsmann, Jens Panse, Jean‐Jacques Kiladjian, Carlos M. DeCastro, +7 more
3citations -
Poster: MDS-112 Normalization of Hematologic and Health-Related Quality of Life Markers in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL2022 Clinical Lymphoma Myeloma & Leukemia article Immunology and Microbiology Complement system in diseases
Dharmik Desai, Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, +5 more
0citations -
Poster: MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment2021 Clinical Lymphoma Myeloma & Leukemia article Immunology and Microbiology Complement system in diseases
Ilene Ceil Weitz, Régis Peffault de Latour, Jeff Szer, Alexander Röth, Britta Höchsmann, Jens Panse, +12 more
0citations -
Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial2024 Acta Haematologica article Immunology and Microbiology Complement system in diseases Open access
Hisakazu Nishimori, Hideyuki Nakazawa, Shinobu Tamura, Toshiki Uchida, Kensuke Usuki, Johan Szamosi, +3 more
4citations -
Pivotal clinical trials in C3 glomerulopathy: answers and remaining uncertainties2026 Nephrology Dialysis Transplantation article Immunology and Microbiology Complement system in diseases Open access
Fernando Caravaca‐Fontán, Annette N. Bruchfeld, Sarah Margaret Moran, Stefanie Steiger, Kate Stevens, Y K Onno Teng, +4 more
0citations